“Waiting helps you as an investor and a lot of people just can’t stand to wait. If you didn’t get the deferred-gratification gene, you’ve got to work very hard to overcome that.” ~Charlie Munger Side Note on Fed: I can’t see FOMC members appreciating the market’s reaction to their message, outlook and July rate hike. They desire a diminishing wealth…
Weekly State of the Market: It’s So Bad, It’s Good?
A financial market resource for the every-day investor and trader.
-
Bull Market Carries On, But It Hasn’t Carried Everything With It
Seth Golden, , Research Reports, 0
September 29, 2017 will mark the final trading day of the Q3 2017 period and with that may come...
-
Morgan Stanley: Weekly Warm-up: A Good Start as Stocks Rally in the Face of Doubt and Higher Rates
Seth Golden, , Research Reports, 0
Last week’s tactical bullish call was met with doubt from clients, which means there is still upside as we...
-
Weekly State of the Market: Yield Boon, Tech/Growth Swoon
Seth Golden, , Research Reports, 0
“In this business, if you’re good, you’re right six times out of ten. You’re never going to be right...
-
Dominating Headlines Keep S&P 500 From Achieving New Highs
Seth Golden, , Research Reports, 0
Long-term investing is largely about corporate earnings, sales and the ability of a corporation to deliver a reasonable return...
-
Pivotal Week Ahead Of An April Snooze-Fest!
Seth Golden, , Research Reports, 0
The coming week will prove a meaningful earnings week, as the Mega-cap Growth companies will be reporting their quarterly...
-
Merrill Lynch: 10 Reasons To Stay Long U.S. Equities
Seth Golden, , Research Reports, 0
Good weekend Finom Group members! This weekend is our “off reporting” weekend, but as always, we desire to offer...
-
Smartwatch Vs. Fitness Tracker: Fitbit Dives Deeper Into Smartwatches As Sales Decline
Seth Golden, , Research Reports, 0
Fitness tracker or a smartwatch? Well, that’s a question that was asked a couple of years ago, but plainly...
-
Growth Vs. Vaccine
Seth Golden, , Research Reports, 0
The J.P. Morgan View Growth versus virus now, vaccine versus virus later —an update on a conflict and a...
Recent Articles
Featured Products
- JPM Market Recap $0.00
- JPM Research Note $0.00
- JP Morgan Market Volatility Report $0.00